← brief for 2026-08-28 · Slowing decline

Sodium-glucose cotransporter-2 inhibitor use and clinical outcomes in patients with cirrhosis: a propensity-matched real-world cohort study.

Key takeaways

In over 10,000 people with cirrhosis, those taking SGLT2 inhibitors (a common diabetes drug) were less likely to die or need a liver transplant over about two years. This study shows a link, not proof that the drug caused the benefit.

Who did this work

Helal E · Shehi E · Al Homaid A · Dervishi M · Tripathi DK

Source

Article · PubMed, the drug frontier · 2026 Aug 11
https://pubmed.ncbi.nlm.nih.gov/42664456/